Cutaneous Lupus Erythematosus – Pipeline Review, 2019

The lupus erythematosus (LE) is characterized as connective tissue autoimmune disorder that affects multiple organs. When lupus-specific skin lesions and non-specific skin lesions occur on the skin it leads to a disorder known as cutaneous lupus erythematosus. There are three subtypes of cutaneous specific lupus erythematosus i.e. chronic cutaneous lupus (CCLE), subacute cutaneous lupus (SCLE), and acute cutaneous lupus (ACLE). Lupus non-specific is related to an autoimmune disorder or systemic lupus erythematosus. Discoid lupus (DLE) is one of the most common types of chronic cutaneous lupus, which is characterized red scaly, thickened patches, which usually appears on nose, ears, cheeks; and sometimes on dorsum of hands, upper back, and v of the neck.

Cutaneous lupus erythematosus affects all age groups. However, women of childbearing ages are mainly at risk of developing cutaneous lupus erythematosus. According to the Lupus Foundation of America (LFA), in 2016, it was estimated that around 1.5 million American are affected by a different form of lupus. Immunosuppressive drugs such as methotrexate, mycophenolate mofetil, cyclosporine, azathioprine, and corticosteroids creams and ointments can be the treatment options for cutaneous lupus erythematosus.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for cutaneous lupus erythematosus. For instance; BIIB059, which is being studied by Biogen, is currently in phase-2 clinical trials for study the efficacy of BIIB059 in reducing disease activity in participants with systemic lupus erythematosus (SLE) with active cutaneous manifestations and joint involvement, and in participants with active cutaneous lupus erythematosus (CLE) Subacute cutaneous lupus erythematosus (SCLE) or chronic CLE, including discoid lupus erythematosus (DLE)) with or without systemic manifestations.

At present around 94% of the pipeline candidates for Cutaneous Lupus Erythematosus are in the phase-1 and phase-2 stage. More than half of the studies are sponsored by industry.

Report Description

The report on ‘Cutaneous Lupus Erythematosus – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for cutaneous lupus erythematosus. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Acromegaly.

The report on ‘Cutaneous Lupus Erythematosus – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products forcutaneous lupus erythematosus


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Cutaneous Lupus Erythematosus


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary